Literature DB >> 24928251

Treatment options for thyroid eye disease.

Angelique J Pillar1, D Chimene Richa.   

Abstract

OPINION STATEMENT: Patients with thyroid eye disease (TED) experience hypertrophy of their extraocular muscles and an increase in intraorbital fat volume leading to eyelid retraction, proptosis, double vision, and optic nerve compression. These orbital changes are thought to be due to a cross-reaction of thyroid stimulating hormone (TSH) with antigens in the orbit. Therefore, the key to treatment is achievement of a euthyroid state in patients with abnormal thyroid function. Cigarette smoking is the strongest modifiable risk factor linked with progression and poor response to treatment. All TED patients should be counseled and offered help with smoking cessation. The treatment of TED symptoms must be customized to each patient, as the degree of orbital involvement can vary. During the active state, evaluation of sight-threatening compressive optic neuropathy and treatment of corneal exposure by an ophthalmologist is crucial to avoid irreversible damage. In most patients, local therapy with artificial tears, gels, and ointments can offer symptomatic relief of irritation and dryness. In addition, antioxidant therapy with selenium has been shown to improve quality of life in patients with mild orbital involvement. Some patients will require systemic oral or IV steroids at the onset of an active inflammatory state. However, approximately one third of patients will not be responsive to steroid therapy alone. In these patients, the addition of orbital radiation or use of immune modulation has shown value. Orbital decompression surgery should be considered for cases of vision-threatening optic neuropathy despite maximal medical therapy. Approximately 3-6 months after cessation of the active state and stabilization of symptoms, rehabilitative treatment may be offered. Treatment is offered in a 3-stage surgical approach with orbital decompression surgery, followed by strabismus surgery for any resultant binocular diplopia, and finally eyelid surgery to address eyelid retraction. Meanwhile, symptomatic diplopia may be addressed with monocular patching or prisms.

Entities:  

Year:  2014        PMID: 24928251     DOI: 10.1007/s11940-014-0303-8

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  14 in total

Review 1.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

2.  Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.

Authors:  George J Kahaly; Susanne Pitz; Gerhard Hommel; Manuela Dittmar
Journal:  J Clin Endocrinol Metab       Date:  2005-07-05       Impact factor: 5.958

3.  Potential utility of rituximab for Graves' orbitopathy.

Authors:  Mario Salvi; Guia Vannucchi; Paolo Beck-Peccoz
Journal:  J Clin Endocrinol Metab       Date:  2013-09-05       Impact factor: 5.958

Review 4.  Cigarette smoking and thyroid eye disease: a systematic review.

Authors:  J Thornton; S P Kelly; R A Harrison; R Edwards
Journal:  Eye (Lond)       Date:  2006-09-15       Impact factor: 3.775

5.  Treatment of thyroid eye disease.

Authors:  Margaret E Phillips; Mehrak M Marzban; Sajeev S Kathuria
Journal:  Curr Treat Options Neurol       Date:  2010-01       Impact factor: 3.598

6.  A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy.

Authors:  C A Gorman; J A Garrity; V Fatourechi; R S Bahn; I A Petersen; S L Stafford; J D Earle; G S Forbes; R W Kline; E J Bergstralh; K P Offord; D M Rademacher; N M Stanley; G B Bartley
Journal:  Ophthalmology       Date:  2001-09       Impact factor: 12.079

7.  Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease.

Authors:  Pari N Shams; Roy Ma; Tom Pickles; Jack Rootman; Peter J Dolman
Journal:  Am J Ophthalmol       Date:  2014-02-26       Impact factor: 5.258

8.  Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone.

Authors:  R Ebner; M H Devoto; D Weil; M Bordaberry; C Mir; H Martinez; L Bonelli; H Niepomniszcze
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

9.  Intraorbital injection of rituximab: a new approach for active thyroid-associated orbitopathy, a prospective case series.

Authors:  G Savino; L Balia; D Colucci; R Battendieri; M Gari; S M Corsello; A Pontecorvi; A Dickmann
Journal:  Minerva Endocrinol       Date:  2013-06       Impact factor: 2.184

10.  Methotrexate for the treatment of thyroid eye disease.

Authors:  Diego Strianese; Adriana Iuliano; Mariantonia Ferrara; Chiara Comune; Immacolata Baronissi; Pasquale Napolitano; Alessia D'Alessandro; Piergiacomo Grassi; Giulio Bonavolontà; Paola Bonavolontà; Antonio Sinisi; Fausto Tranfa
Journal:  J Ophthalmol       Date:  2014-01-08       Impact factor: 1.909

View more
  3 in total

1.  Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease.

Authors:  David B Granet; Nickisa Hodgson; Kyle J Godfrey; Ricardo Ventura; Don O Kikkawa; Leah Levi; Michael Kinori
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-10       Impact factor: 3.117

2.  Treatment of ocular motor palsies.

Authors:  Imran Jivraj; Vivek Patel
Journal:  Curr Treat Options Neurol       Date:  2015-03       Impact factor: 3.598

Review 3.  Virtual Surgical Planning for Orbital Reconstruction.

Authors:  Srinivas M Susarla; Katherine Duncan; Nicholas R Mahoney; Shannath L Merbs; Michael P Grant
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Oct-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.